OCA
CNTB

Octagon Capital Advisors’s Connect Biopharma Holdings CNTB Stock Holding History

Octagon Capital Advisors’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-450,000
Closed -$581K – 38
2022
Q3 		$581K Buy
+450,000
New +$541K 0.1% 33
2022
Q2 		– Sell
-279,921
Closed -$845K – 21
2022
Q1 		$845K Hold
279,921
– – 0.18% 23
2021
Q4 		$1.44M Sell
279,921
-46,222
-14% -$514K 0.28% 27
2021
Q3 		$7.79M Sell
326,143
-47,349
-13% -$1.07M 1.92% 15
2021
Q2 		$7.29M Hold
373,492
– – 1.51% 19
2021
Q1 		$6.91M Buy
+373,492
New +$6.36M 2.6% 16

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Octagon Capital Advisors's CNTB Position: Q4 2022 in Review

Octagon Capital Advisors sold out of Connect Biopharma Holdings (CNTB) in Q4 2022, closing a stake of 450,000 shares — an estimated $581K sold.

Octagon Capital Advisors first reported a position in CNTB in Q1 2021 and held it in 6 quarters. The position peaked at $7.79M in Q3 2021. 20 funds tracked by Wall St. Rank hold CNTB as of Q4 2022.

  • Octagon Capital Advisors reported no remaining Connect Biopharma Holdings position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 450,000 Connect Biopharma Holdings shares in Q4 2022, an estimated $581K.
  • Octagon Capital Advisors first reported a position in Connect Biopharma Holdings in Q1 2021 and held it in 6 quarters.
  • Octagon Capital Advisors's Connect Biopharma Holdings position peaked at $7.79M in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.